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SUMMARY 
 
   Purpose: to evaluate the daily practice of management of early inoperable lung cancer (stage I). 
   Materials and methods: The analysis was based on a questionnaire which was sent to participated 
centers. Between 1982 and 1994, 123 patients with an early stage I inoperable lung cancer were 
treated with definitive irradiation in the different institutions. The survival distributions were estimated 
by the Kaplan-Meier method. The following covarties were analyzed: age, gender, Karnofsky status, 
symptoms, diagnostic work-up, T stage, tumour size, tumour location, histology, respiratory and car-
diac contra-indication. The univariate analysis was performed using log-rank test. Cox regression 
models were used to find the independent prognostic factors. 
   Results: The 2 and 5-year survival rates were 34% and 8% respectively. The 5-year local failure 
rate was 42 % for T1 and 82% for T2. In a multivariate analysis, the most important prognostic factors 
for survival were the performance status and the stage. After adjustment for these two covariates,  
the total dose delivered had no impact for the range of doses used in this series. 
   Conclusions: Our poor data outlined the needs for better radiation technique and for a better 
staging system. 
 
INTRODUCTION 
 
   The management of early inoperable 
lung cancer (stage I, II) remains a contro-
versial issue between tenants of an aggre-
ssive approach aiming at cure and those 
in favor of a more conservative approach, 
from a wait and see policy to moderate 
doses of radiotherapy. Furthermore, even 
after a curative course of radiation, results 
vary between different series leading from 
an optimistic view (radiation may be a cu-
rative modality) to a pessimistic view (only 
surgery may cure such patients). This was 
well illustrated by several surveys on lung 
cancer management [22]. Indeed, 5-year 
survival rates vary from 5 to 31% for sta-
ge I disease [3-6,8,9,12-16,19,20,21,24]. 
Also, there are still some questions related 
directly to the radiation treatment modality: 
total doses, volume to be treated, the role 
of elective mediastinal irradiation, and the 
place for conformal 3D radiotherapy or 
endoluminal brachytherapy. 
   During the last years, our network 
of «rare disease» conducted several 
reviews. The multicentric character of our 
systematic database allows us to partially 
avoid a possible bias of patient selection. 
This approach may more reflect the daily 
practice of radiation oncology as we regi-
stered in our study all cases treated 
in the participating institutions. 
 
MATERIAL AND METHODS 
 
   A questionnaire was sent to participants 
of our network. Criteria were to have 
a stage I non-small cell lung cancer tre-
ated between 1982 and 1994 by exclusive 
external radiotherapy without any chemo-
therapy and no prior history of cancer. 
   Survival duration was calculated from 
the first day of irradiation. The survival 
distributions were estimated by the Kaplan 
Meier method. The same method was 
used to calculate the risk of local failure. 
The impact of some covariates was 
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analyzed: age (≤70 years vs. > 70), gen-
der, Karnofsky index (≤ 70 vs. 70), sym-
ptoms (No vs. yes), diagnostic work-up 
(local only only vs. distant), T1 vs. T2, 
tumor size (<2cm, 2-4, >4 cm), tumor 
location (right versus left), histology 
(squamous vs. other), respiratory (no vs. 
yes) and cardiac contra-indication (no vs. 
yes). Univariate analysis for these cova-
riates was done by non-parametric log 
rank tests. Cox regression models were 
used to determine the independent pro-
gnostic value of these covariates. A for-
ward stepwise method was applied to se-
lect the variables to be included in the final 
model. The distribution of the time to local 
failure and of the survival without relapse 
was also estimated with an actuarial 
method. All reported p values are twotai-
led, with a level of significance of 5%. 
    This series included 123 patients, 
112 men and 11 women, with a mean age 
of 71.8 years ranging from 50 to 88 years). 
Contraindications to surgery were poor 
respiratory functions (60 patients), old age 
(34 patients), cardiac function (20 pa-
tients), and general physical conditions 
(12 patients) but also patient refusal (9 pa-
tients). These co morbidities had an im-
pact on their performance status: 29 had 
a Karnofsky index inferior to 80 and 8 pa-
tients had severe limitation with an index 
below 50. There were 38 T1NO and 85 
T2NO tumors. For the latter, tumor size 
varied from 3 to 10 cm. The initial staging 
procedure was different from one center 
to another: chest CT was performed 
in almost all patients (106 patients) but 
only 53 patients had a work-up including 
an upper abdominal investigation by CT 
or echography, 25 had a brain CT or MR 
and 29 patients a bone scintigraphy. 
Patients were treated with different 
radiation schedules according to the local 
policy including split course, continuous 
daily radiation doses and an hyper-
fractionated schedules with a 2 week 
interruption between the 3 radiation 
courses. Continuous daily irradiation deli-
vered doses between 1.8 and 4 Gy per 
fraction: total physical dose and fraction 
size are listed in Table 1. The dose were 
asked to be reported according to the 
ICRU definition. For the purpose of this 
study, the doses were converted in tumor 
equivalent doses for 2 Gy per fraction 
without taking into account the treatment 
duration (10). For the 2 Gy equivalent 
radiation doses, 2 patients received less 
than 45 Gy, 56 between 46 and 59 Gy and 
65 patients more than 60 Gy. Ten out 
of 38 T1N0 received less than 60 Gy and 
only 37 patients out of the 85 T2N0 
received 60 Gy or more. 
   Concerning the clinical target volume, 
there was a wide variation between 
the centers and the data for the different 
possible lymph node areas (ipsi and 
contralateral hilum, lower and upper 
mediastinum, supraclavicular lymph no-
des) were not always available: only 
the information for the mediastinum and 
the supraclavicular lymph nodes were well 
reported. When an elective mediastinal 
irradiation was performed, the volume was 
later reduced to boost only the gross 
tumor volume using oblique or lateral 
fields. Seventy-two patients had an irra-
diation including an elective mediastinal 
irradiation to a dose at least of 45 Gy, 
10 received less than 45 Gy and 41 pa-
tients had no mediastinal irradiation. Only 
18 patients had an irradiation of the supra-
clavicular nodes. 
 
Table 1. Relation between total dose and fraction size. 
 
Fraction size in Gy 
Total 
Dose (Gy) < 2 2 - 2.2 2.3 - 2.6 2.7 - 2.9 3 - 3.5 4  
< 40  1   1  2 
40 - 49   1  1 9 11 
50 - 52 1  2  5  8 
53 - 57 1 6 1 28   36 
58 - 62 1 12 1  37  51 
63 - 67  7 1    8 
68 - 74  6 1    7 
 3 32 7 28 44 9 123 
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RESULTS 
 
   The 2 and 5-year survival rates were 
respectively 34% and 8% and the 2 
and 5-year survival without relapse 29% 
and 7%. The 2-year survival rate dropped 
from 52% for T1 tumor to 21% for T2 
lesions and the 5-year survival rate from 
13% to 1%. Altogether 6 patients were 
alive 5 years after the treatment including 
5 T1 and 1 T2. No difference was 
observed at 2 years between patients 
receiving less than 60 or more than 60 Gy: 
the 2 year survival rates were 30% 
for doses between 46 and 59 Gy and 32% 
for doses of 60 Gy or more. 
   Local recurrence as component of failure 
was observed in 36 patients while distant 
metastases were seen in 24 patients. No di-
fference was observed in term of loco-
regional relapse between T1 and T2 while 
T2 had more distant metastases (18.3% 
vs. 9.8%) (Table 2). If the risk of local 
recurrence is expressed in an actuarial 
way, the 5-year local failure rates were 
respectively 42% for T1 and 82% for T2 
(Fig. 1). In this series, we did not observe 
any influence of the total dose delivered 
either for the whole series, T1 or T2. 
The total dose of irradiation had no impact 
on the tumor control for the whole series, 
T1 or T2 tumor (Table 3). However, only 
one relapse was observed amongst 
the 11 patients with a tumor smaller than 
2 cm, all had received doses in excess 
of 55 Gy. 
   A mediastinal relapse was observed 
in 6 cases either alone (one patient) 
or with a local relapse (5 patients). The pa-
tient with only a mediastinal relapse had 
received less than 45 Gy to the media-
stinum. Amongst the 5 patients with a local 
and mediastinal relapse, three had no me-
diastinal irradiation and 2 had received 
more than 45 Gy to the mediastinum. 
There was no single supraclavicular fai-
lure. 
   In univariate analysis, the only significant 
prognostic factors on survival were 
the performance status, the stage and 
the tumor size; gender and tumor localiza-
tion had also an influence with better 
observed survival for female and right side 
lesions without reaching statistical signify-
cation (Table 4). In a multivariate analysis, 
only performance status (p= 0.003) 
and stage (p=0.02) were important 
prognostic factors. The total dose had no 
influence on the survival. 
 
 
Table 2. Stage I lung cancer : pattern of relapse. 
 
 All T1 T2 
 123 38 85 
Local 25 6 19 
Local + Mediastinal 5 2 3 
Local + Distant 4 2 2 
Mediastinal only 1  1 
Distant met. 19 6 13 
Loc+Mediastinal+Met. 1  1 
 
Table 3. Locoregional relapses versus equivalent 2 Gy total doses (numbers in parentheses refers to the total number 
of patients). 
 
 0-45 Gy 46-59 Gy 60 Gy or more 
All 50% (1/2) 
20% 
(11/56) 
37% 
(24/65) 
T1 0 30% (3/10) 
25% 
(7/28) 
T2 50% (1/2) 
18% 
(8/46) 
43% 
(16/37) 
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Fig. 1. T1 - T2 NO NSC LUNG Ca: Exclusive RT Actuarial Risk of Local Relapse.  
Fig. 1. T1 - T2 NO NSC LUNG Ca: Exclusive RT Actuarial Risk of Local Relapse. 
 
Table 4. Prognostic factors for stage I non small cell lung cancer: an univariate analysis. 
 
Covariate N 2 Years rate 5 Years rate p 
Age     
≤ 70 yrs 56 38% 7% 0.45 
> 70 65 30% 8%  
Sex     
Male 110 31% 7% 0.10 
Female 11 55% 14%  
Karnofsky     
≤ 70 29 21% 3% 0.01 
> 70 65 38% 9%  
Symptoms     
No 66 33% 10% 0.62 
Yes 28 41% 5%  
Diagnostic work-up     
Local only 60 35% 4% 0.99 
Distant test 61 32% 15%  
Staging     
T1 38 52% 16% < 0.01 
T2 83 25% 4%  
Tumor size     
< 2 cm 23 44% 28% 0.02 
2 - 4 cm 62 37% 4%  
> 4 cm 36 21% 6%  
Tumor localisation     
Right 60 27% 3% 0.12 
Left 59 38% 13%  
Histology     
Squamous 90 30% 9% 0.63 
Other 31 43% 4%  
Respiratory contra-indic.     
No 57 30% 20% 0.21 
Yes 60 39% 9%  
Cardiac contra-indic.     
No 97 37% 8% 0.39 
Yes 20 25% 13%  
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DISCUSSION 
 
   This series includes unselected patients 
treated in different institutions over Europe 
and is a good illustration of the daily 
practice in the management of early non-
small cell lung cancer. Those results 
remain within the limits of a large review 
made by the Cochrane group: the 2-year 
survival rates range from 22 to 72% and 
the 5-year survival rate from 0 to 42%. 
Results may appear very dismal in con-
trast to some series from single institutions 
but outlined the pessimistic point of view 
of the community when dealing with 
inoperable lung cancer (Table 5) [3-9,12 
-14,16,19,20,24]. 
 
 
 
Table 5. Irradiation for early NSC lung.  
 
No Radiation scheme Elective nodal Survival rate (%) Authors 
of pts Gy weeks irradiation 3 years 5 years 
Burt et al (1989) 133 50 - 55 3 No  20 
Cheung et al (2000) 102 48 4 No 35 16 
Coy and Kennely (1980) 141 50 - 57 4 Yes 18 10 
Dosoretz et al (1992) 152 50 - 70 5 - 7 Yes  10 
Gauden et al (1995) 347 50 4 Yes  27 
Gouders et al 123 40 - 70  Yes (59%) 18 5 
Graham et al (1995) 150 60 6 Yes  14 
Krol et al (1996) 108 60 - 65 6 - 7 s No 31 15 
Morita et al (1997) 66 55 - 74 6 - 7 Yes  31 
 83   No  15 
Noordijk et al (1988) 50 60 6 - 7 s No  16 
Sandler et al (1990) 77 60 6 Yes 21 17 
Sibley et al (1998) 141 64 5 - 7 Yes (73%)  13 
Slotman et al (1996) 31 48  No 42 8 
Zhang et al (1989) 44 55 - 70 6 - 7 Yes  16 
(s = split course)       
 
 
   Why are the results so dismal in contrast 
to some of the reported series in lite-
rature? Several explanations are possible 
related either to the initial staging 
procedure or to the radiation technique 
itself. Indeed in the current series, many 
patients had a staging procedure limited 
to a chest CT. It was very rare to perform 
a brain CT or MR and even an upper 
abdominal investigation was only perfor-
med in one out of three patients. Those 
findings are in good concordance with 
a survey of radiation practice performed 
in 1994: in daily practice CT of the brain 
was performed in less than 50% of the 
centers with a great variation between 
countries (from 62% in France to 5% 
in Great Britain) [22]. 
   The T stage or the tumor size is an im-
portant prognostic factor. In the current 
series, the 5-year survival rate dropped 
from 13% for T1 to 1% for T2N0. This is 
in agreement with most published series. 
There is also a need for better defining T2: 
in the current series, T2 included tumors 
as large as 10 cm. This may explain 
partially the poor survival and local control 
and outlines the necessity to move slowly 
away from the classical TNM classi-
fication: tumor volume should be taken 
into account especially when dealing with 
radiation treatment. The second expla-
nation may be the suboptimal radiation 
technique: doses vary from 32 to 74 Gy 
while some patients were even treated 
with a split course schedule. In the current 
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series, higher biological dose yield better 
survival and local control for T1N0 tumor. 
It is interesting that improving the radiation 
schedule may lead to better survival: 
in the CHART (Continuous, Hyperfractio-
nated, Accelerated, Radiation Treatment) 
randomized trial, an analysis of stage 
I disease showed a 4-year survival rate 
of 12% after 60 Gy in 6 weeks and 18% 
for the CHART protocol [1,17]. Another 
approach could be to use a chemora-
diation program either with an induction 
schedule or a concurrent approach. 
Several trials have demonstrated a benefit 
due to an improvement in the control 
of the metastatic disease with an induction 
schedule or due to a better local control 
when a concurrent approach is used 
[1,7,11,18]. However, most patients trea-
ted in those trials have usually stage III 
disease, a good performance status and 
a complete initial staging evaluation. 
   The clinical target volume remains 
a controversial issue: should the irradiation 
be limited to the gross tumor volume 
or should an elective mediastinal irradia-
tion be performed? In the paper of Morita 
including 149 patients there was some su-
ggestion for better survival for patients re-
ceiving mediastinal irradiation: the 5-year 
survival rate rose from 15% to 31% 
in case of elective mediastinal irradiation 
[13]. Nevertheless, this was partially 
related to the initial tumor location (near 
to the mediastinum) and to the histological 
subtype (adenocarcinoma vs. squamous 
cell ca). Sibley et al noticed an improved 
local control 2 years after a prophylactic 
mediastinal irradiation without better ove-
rall survival [19]. In different series, there 
was no elective mediastinal irradiation and 
mediastinal failures were rare: Slotman 
et al reported 3 locoregional relapses 
in a series of 31 patients, Krol et al 4 out 
of 50 patients and Cheung et al 4 out 
of 102 patients [4,12,20]. Furthermore, 
inoperable stage I patients have often very 
poor lung functions and the volume of irra-
diation is mostly determined by the patient 
lung function. This volume may also be 
influenced by the quality of the initial 
staging procedure. Mediastinosocopy was 
not routinely performed and the radiation 
oncologist based his judgment on the chest 
CT. In the future PET scan may be a use-
ful tool to help us to better delineate our 
target volume: 73 patients had a CT, a PET 
scan and a surgical resection. Radiation 
volumes were defined by CT and PET 
scans and compared to the surgical data; 
PET changed the CT defined volume 
in 45 out of 73 patients and did not include 
in 8 cases all the positive lymph nodes 
(5 misinterpretations of lymph node loca-
lization and 3 cases of minimal disease) 
[23]. 
   Tumor control is directly related to the 
total dose and the tumor size whereas 
the late morbidity is directly influenced by 
the total dose, the fraction size and 
the volume irradiated. Tolerance of normal 
lung is one of the limiting factors when 
irradiating a patient suffering from lung 
cancer. This is particularly the case 
for patients with a contraindication to sur-
gery due to poor lung functions. On the 
other side, the probability of local control is 
directly influenced by the total dose 
delivered. So, this group of patients should 
be a good candidate for 3D conformal 
radiotherapy. 
   In conclusion, the poor results achieved 
in the current series of patients just reflect 
the lack of an aggressive management 
including a suboptimal initial workup and 
radiation technique. The data available 
in literature shows clearly that radiation 
may be a curative modality providing 
an adequate radiation schedule with the 
aim of delivering biological equivalent 
doses in excess of 60 Gy, while keeping 
in mind the tolerance of normal tissues. 
Better radiation techniques are mandatory 
for early T1N0 tumors. 
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